Why Synthetic Vasopressin and Oxytocin Analogs Should be Considered in the Treatment of Cardiogenic Shock: A Personal Perspective

Burton M Altura, Asefa Gebrewold, Anthony Carella and Bella T Altura

Department of Physiology and Pharmacology, The State University of New York Downstate Medical Center, USA
Department of Medicine, The State University of New York Downstate Medical Center, New York, USA
Department of Cardiovascular and Muscle Research, The State University of New York Downstate Medical Center, USA
Department of Molecular and Cellular Science, The State University of New York Downstate Medical Center, USA
Bio-Defense Systems, Inc, Rockville Centre, New York, USA
Orient Biomedical, Eastero, Florida, USA

^*Correspondance to: Burton M. Altura 

 PDF  Full Text DOI: 10.25107/2474-1647.1943

Abstract

Cardiac instability can be brought about by a number of hemodynamic dysfunctions such as deficits in myocardial ventricular or atrial contractility, Myocardial Infarction (MI), electricalconduction disturbances, myocardial valvular problems, structural changes in the pericardium, coronary arterial flow problems or combinations of these factors. Cardiogenic Shock (CS) is characteristically defined as a cardiac disorder which results in clinical, biochemical and molecular cell manifestations in inadequate tissue and cellular perfusion. Clinically, the patient presents with persistent hypotension which is unresponsive to volume replacement in conjunction with endorgan hypoperfusion requiring intervention with pharmacological/mechanical support. The end result of this hypoperfusion is a deficit in coronary microcirculatory blood flow and nutrition to the tissues and cells of the ventricles and atria.

Keywords

Cite the article

Altura BM, Gebrewold A, Carella A, Altura BT. Why Synthetic Vasopressin and Oxytocin Analogs Should be Considered in the Treatment of Cardiogenic Shock: A Personal Perspective. Clin Surg. 2018; 3: 1943.